OpenEvidence secured $250 million in Series D funding on Wednesday, propelling its valuation to $12 billion as the startup seeks to dominate the medical AI sector. Thrive Capital and DST co-led the massive investment round, signaling robust investor confidence even as tech giants OpenAI and Anthropic launch competing healthcare initiatives.
Exponential Growth and Silicon Valley Dominance
The latest capital injection effectively doubles the company’s market value in less than a quarter. In October, OpenEvidence announced a $200 million raise led by GV at a $6 billion valuation. This rapid appreciation brings the firm’s total funding to $700 million. The cap table features a prestigious roster of backers, including Nvidia, Sequoia, Kleiner Perkins, Blackstone, Bond, Craft Ventures, and the Mayo Clinic.
Defining Medical Superintelligence for Doctors
OpenEvidence functions as a high-precision, AI-driven medical information ecosystem. While the previous digital era relied on platforms like WebMD, OpenEvidence specifically engineers its “Medical Superintelligence” for clinical professionals. This professional focus differentiates the platform from consumer-centric tools like ChatGPT’s health offerings or Anthropic’s Claude for Healthcare, which serves a broader mix of patients, payers, and providers.
Surpassing $100 Million in Annual Revenue
The platform’s adoption metrics reflect a significant shift in how healthcare providers access data. In December alone, OpenEvidence facilitated 18 million clinical consultations for verified U.S. healthcare professionals—a staggering increase from the 3 million monthly searches recorded just one year ago. This surge in utility has translated into financial success, with the company confirming it has already surpassed the $100 million revenue milestone. The platform currently maintains a free, ad-supported model to ensure immediate accessibility for the medical community.
